European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein - hemorrhagic fever, ebola - vaccines - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus.the use of ervebo should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorrhagic fever, ebola - vaccines - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.,

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - bnt162b2 -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tozinameran 0.5 mg/ml equivalent to 30 µg/0.3ml dose;  ;  ;  ;  ; tozinameran 0.5 mg/ml equivalent to 30 µg/0.3 ml dose - concentrate for injection - 0.5 mg/ml - active: tozinameran 0.5 mg/ml equivalent to 30 µg/0.3ml dose         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol dibasic sodium phosphate dihydrate monobasic potassium phosphate potassium chloride sodium chloride sucrose water for injection active: tozinameran 0.5 mg/ml equivalent to 30 µg/0.3 ml dose excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sucrose water for injection - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 12 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Canada - English - Health Canada

astrazeneca canada inc - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - azd1222 -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - bnt162b2 -

Canada - English - Health Canada

janssen inc - ad26.cov2.s [recombinant] - suspension - 50000000000vp - ad26.cov2.s [recombinant] 50000000000vp

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - azd1222 -

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml);  ;  ;   - solution for injection - active: chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml)       excipient: disodium edetate dihydrate ethanol histidine histidine hydrochloride monohydrate magnesium chloride hexahydrate polysorbate 80 sodium chloride sucrose water for injection - covid-19 vaccine astrazeneca is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations.